| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Letters to the Editor |
National Institute of Child Health and Human Development, National Institutes of Health, Pediatric and Reproductive Endocrinology Branch Bethesda, Maryland 20892-1583
Address correspondence to: Evangelia Charmandari, M.D., Pediatric and Reproductive Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, 10 Center Drive, Building 10, Room 9D42, Bethesda, Maryland 20852-1583.
To the editor:
We thank Dr. R. L. Rosenfield for his comments on our paper (1) and for the opportunity to clarify these points further.
We recommend administration of the higher portion of the daily hydrocortisone dose in the morning because serum cortisol concentrations attained after the administration of the evening hydrocortisone dose decline and reach undetectable concentrations by 0400 h, when a precipitous rise in 17-hydroxyprogesterone is observed. This point is illustrated in Fig. 2 of our paper (1). Of course, one could suggest that administration of a higher dose of hydrocortisone in the evening might successfully suppress the early morning rise in ACTH and 17-hydroxyprogesterone concentrations because of the higher peak cortisol concentrations attained. However, in our studies of cortisol pharmacokinetics, we have demonstrated that the half-life of serum cortisol is short (8090 min) and that after the iv administration of hydrocortisone sodium succinate in a dose of 15 mg/m2, serum cortisol concentrations decline monoexponentially and reach undetectable levels within 46 h (2). Therefore, it is likely that even if we give the higher portion of daily hydrocortisone dose in the evening, we may not achieve sufficient suppression of the hypothalamic-pituitary-adrenal axis between 0400 and 0800 h.
As for prednisone or dexamethasone, we suggest that they be given for a few days only in patients with inadequate control, in whom standard therapy with hydrocortisone failed to control adrenal hyperandrogenism. However, we would be reluctant to recommend their regular use in the management of patients with congenital adrenal hyperplasia because of their well documented detrimental effects on growth and the associated adverse effects of long-acting glucocorticoids (3, 4, 5, 6).
Received February 22, 2002.
References
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |